The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study).
 
Robert J. Motzer
No Relationships to Disclose
 
Camillo Porta
No Relationships to Disclose
 
Masatoshi Eto
No Relationships to Disclose
 
Thomas Powles
No Relationships to Disclose
 
Viktor Grünwald
No Relationships to Disclose
 
Thomas E. Hutson
No Relationships to Disclose
 
Boris Alekseev
No Relationships to Disclose
 
Sun Young Rha
No Relationships to Disclose
 
Evgeny Kopyltsov
No Relationships to Disclose
 
María José Méndez Vidal
No Relationships to Disclose
 
Sung-Hoo Hong
No Relationships to Disclose
 
Anil Kapoor
No Relationships to Disclose
 
Teresa Alonso Gordoa
No Relationships to Disclose
 
Jeffrey C. Goh
No Relationships to Disclose
 
Jaime R. Merchan
No Relationships to Disclose
 
Alan D. Smith
No Relationships to Disclose
 
Kalgi Mody
No Relationships to Disclose
 
Rodolfo F. Perini
No Relationships to Disclose
 
Dongyuan Xing
No Relationships to Disclose
 
Toni K. Choueiri
No Relationships to Disclose